



UTILITY PATENT APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: VAS-4761CONDIV

Page 1 of 2

Title: Radially Expandable Tape-Reinforced Vascular Grafts

Express Mail Label No.: EL599141019US

	APPLICATION ELEMENTS	ADDRESS TO: Commissioner for Patents Box Patent Application					
INVENTORS: Donald Shannnon, John McIntyre, Chris Kuo, Chris McCollam, Robert Peterson Washington, D.C. 20231							
	Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	11. X Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations					
2.	X Specification [Total Pages 23]	12. X Preliminary Amendment Subnitted					
3.	X Drawing(s) (35 USC §113)	13. Return Receipt Postcard (MPEP 503)					
4.	X Signed Declaration [Total Pages 3]	14. Small Entity Statement(s)					
	a. Newly executed (original or copy)	15. Certified Copy of Priority Documents (s)					
	b. X Copy from a prior application (37 CFR §1.63(d))	16a. Cancel in the application original claimsbefore calculating the filing fee					
	(Note Box 5 below) i. DELETION OF INVENTOR(S)	16b. Amend the specification by inserting before the first line the					
	Signed statement attached deleting inventor	sentence:This is a Continuation, Divisional, Continuation-in-part, of application					
	named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)	, filed					
	37 Of R 331.00(0)(2) and 1.00(0)	16c. I hereby verify that the attached papers are a true copy of the					
5.	Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application,	latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was					
	from which a copy of the oath or declaration is supplied	Signed. I hereby verify that the papers are a true copy of the latest					
	under Box 4b, is considered as being part of the disclosure of the accompanying application and is	signed prior application number, filed and further that all statements made herein of my own knowledge					
	hereby incorporated by reference therein	are true; and further that these statements were made with the knowledge that willful false statements and the like so made are					
6.	Microfiche Computer Program	punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false					
_		statements may jeopardize the validity of the application or any					
7.	Nucleotide and/or Amino Acid Sequence Submission	patent issuing thereon.					
8.	Assignment Papers with recordation sheet (pages)						
		16d. Other:					
9.	37 CFR §3.73(b) Statement Power of Attorney						
10	English Translation Document	16e. Other					
10.	English Hanslauon Document						
17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:							
Continuation Divisional Continue to the state of the stat							
Continuation Divisional Continuation-in-part (CIP) of prior application No.: <u>09/201,953</u>							



UTILITY PATENT APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: VAS-4761CONDIV

Page 2 of 2

Title: Radially Expandable Tape-Reinforced Vascular

Grafts

Express Mail Label No.: EL599141019US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	22-20=	2	X \$ <u>18</u> =	\$36
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	2-3=	0	\$ <u>80</u> =	\$0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ <u>270 =</u>	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$710
-				TOTAL =	\$746

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 501225 (Docket ***). (For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. X Fees required under 37 CFR §1.16
- b. X Fees required under 37 CFR §1.17
- c. Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME
Peter Jon Gluck, Reg. No. 38,022

SIGNATURE

DATE
July 24, 2001

CORRESPONDENCE ADDRESS
Edwards Lifesciences LLC
Law Dept.
One Edwards Way

Irvine, California 92614
Telephone: (949) 250-6801 Fax: (949) 250-6850

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above -identified document is being deposited with the United States Postal Service as Express Mail No: EL599141019US in an envelope addressed to Box Patent Application, Commissioner for Patents, Washington, D.C. 20231 on July 24, 2001.

Jan Lamonica